A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
Status:
Completed
Trial end date:
2020-11-17
Target enrollment:
Participant gender:
Summary
This study further evaluates the efficacy of bermekimab in treating moderate to severe
hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of
bermekimab, 1/3 will receive alternating every other week injections of bermekimab or
placebo, and 1/3 will receive weekly injections of placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC XBiotech, Inc.